The administration of fruquintinib must follow strict medical guidance. It is commonly indicated for the treatment of metastatic colorectal cancer. The recommended dose is 5 mg (1 capsule) once daily, taken orally on an empty stomach (at least 2 hours after a meal or 1 hour before a meal). It is administered for 3 consecutive weeks followed by a 1‑week rest period, forming a 4‑week treatment cycle. If a dose is missed, there is no need for a make‑up dose; take the next dose at the scheduled time.
Specific Administration Instructions & Precautions
Standard Dosage and Cycle
5 mg once daily, taken for 21 consecutive days followed by a 7‑day rest period.
The physician may adjust the dosage (e.g., reduce to 4 mg or 3 mg) based on the patient’s tolerability, side effects, or treatment response.
Administration Requirements
Swallow the capsule whole; do not chew, split, or crush it.
Take on an empty stomach to minimize the effect of food on drug absorption.
If vomiting occurs after dosing, do not take an extra dose.
Adverse Reactions to Monitor
Hypertension
Blood pressure should be monitored regularly during treatment. Antihypertensive treatment or temporary drug interruption may be needed if abnormalities develop.
Proteinuria
Monitored by routine urinalysis; temporary or permanent treatment discontinuation may be required in severe cases.
Liver dysfunction
Regular testing of liver enzymes, bilirubin, and other liver function markers is recommended.
Drug Interactions
Avoid concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole) or inducers (e.g., rifampicin), as they may alter drug efficacy or increase toxicity. Medical evaluation and dosage adjustment are mandatory if co‑administration is unavoidable.
Important Warnings
Dosage adjustment as prescribed
Use with caution in patients with hepatic or renal impairment and elderly patients; individualized dosage adjustment may be necessary.
Contraindicated populations
Contraindicated in pregnant women, breastfeeding women, and patients hypersensitive to any ingredient. Use with caution in patients at high risk of severe bleeding or with uncontrolled hypertension.
Medical guidance
Regular follow‑up examinations are required during treatment. Seek immediate medical attention in the event of emergencies such as dyspnea, severe diarrhea, or hematemesis.
Fruquintinib is a prescription medication. The treatment regimen must be prescribed by an oncologist based on the patient’s condition. Do not adjust the dosage or discontinue treatment without medical advice.
